Literature DB >> 25081325

New perspectives on target intraocular pressure.

Colin I Clement1, Shibal Bhartiya2, Tarek Shaarawy3.   

Abstract

The evidence in support of intraocular pressure (IOP) lowering to reduce risk of glaucoma onset or progression is strong, although the amount and quality of IOP reduction is less well defined. The concept of a target IOP includes a percentage reduction, calculated IOP, or a predetermined IOP figure or range. Yet none of these strategies have been validated. In addition, our understanding of the way IOP influences glaucoma risk is continuously evolving. Examples of this include the data on IOP fluctuation and lamina cribrosa and cerebrospinal fluid pressure differentials. That these variables are not included in target IOP calculation potentially undermines its accuracy and usefulness. We summarize the evidence for target IOP, new developments in our understanding of IOP and glaucoma pathogenesis, as well as emerging strategies for setting targets and assessing response to treatment.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  glaucoma; intraocular pressure

Mesh:

Year:  2014        PMID: 25081325     DOI: 10.1016/j.survophthal.2014.04.001

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  10 in total

1.  Micro-invasive 360-degree suture trabeculotomy after successful canaloplasty – one year results.

Authors:  Anna-Maria Seuthe; Kai Januschowski; Peter Szurman
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-01       Impact factor: 3.117

2.  A modified scleral dissection technique with suprachoroidal drainage for canaloplasty.

Authors:  Peter Szurman; Kai Januschowski; Karl Thomas Boden; Gesine Bettina Szurman
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-12-14       Impact factor: 3.117

3.  Modified canaloplasty with suprachoroidal drainage versus conventional canaloplasty-1-year results.

Authors:  Anna-Maria Seuthe; Ciprian Ivanescu; Stephan Leers; Karl Boden; Kai Januschowski; Peter Szurman
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-05-10       Impact factor: 3.117

4.  Long-term assessment of prostaglandin analogs and timolol fixed combinations vs prostaglandin analogs monotherapy.

Authors:  Ai-Wei Liu; Lin-Yang Gan; Xiang Yao; Jian Zhou
Journal:  Int J Ophthalmol       Date:  2016-05-18       Impact factor: 1.779

Review 5.  [Basic biochemical processes in glaucoma progression].

Authors:  N von Thun und Hohenstein-Blaul; S Kunst; N Pfeiffer; F H Grus
Journal:  Ophthalmologe       Date:  2015-05       Impact factor: 1.059

6.  Comparison of total/active ghrelin levels in primary open angle glaucoma, pseudoexfoliation glaucoma and pseudoexfoliation syndrome.

Authors:  Numan Eraslan; Ufuk Elgin; Emine Şen; Aytul Kilic; Pelin Yilmazbas
Journal:  Int J Ophthalmol       Date:  2018-05-18       Impact factor: 1.779

7.  Water Drinking Test: Intraocular Pressure Changes after Tube Surgery and Trabeculectomy.

Authors:  Mohammad Reza Razeghinejad; Zahra Tajbakhsh; Mohammad Hossein Nowroozzadeh; Masoumeh Masoumpour
Journal:  J Ophthalmic Vis Res       Date:  2017 Oct-Dec

8.  Inhibition on Apoptosis Induced by Elevated Hydrostatic Pressure in Retinal Ganglion Cell-5 via Laminin Upregulating β1-integrin/Focal Adhesion Kinase/Protein Kinase B Signaling Pathway.

Authors:  Yi Li; Yan-Ming Chen; Ming-Ming Sun; Xiao-Dan Guo; Ya-Chen Wang; Zhong-Zhi Zhang
Journal:  Chin Med J (Engl)       Date:  2016-04-20       Impact factor: 2.628

9.  Fluctuation of intraocular pressure in glaucoma patients before and after trabeculectomy with mitomycin C.

Authors:  Joanna Wasielica-Poslednik; Julian Schmeisser; Esther M Hoffmann; Veronika Weyer-Elberich; Katharina Bell; Katrin Lorenz; Norbert Pfeiffer
Journal:  PLoS One       Date:  2017-10-04       Impact factor: 3.240

10.  The Association Between Intraocular Pressure and Visual Field Worsening in Treated Glaucoma Patients.

Authors:  Jithin Yohannan; Michael V Boland; Pradeep Ramulu
Journal:  J Glaucoma       Date:  2021-09-01       Impact factor: 2.290

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.